tirzepatide cardiovascular outcomes trial results july 2025 risk Achieving BMI <25 kg/m2 was associated with reduced Tirzepatide Reduces Risk of Diabetic – tirzepatide cardiovascular outcomes trial results

Together, you can make adjustments as needed, monitor for side effects, and keep your treatment on track to achieve your health goals

Your body gradually develops tolerance to the medication's digestive effects

Serious side effects were rare, occurring in about 4% of participants in both the retatrutide and the placebo group, so this risk wasnt higher because of retatrutide

GLP-1 is an incretin hormone that is released by your digestive tract and plays a large role in your appetite and digestion

doi: 10.1155/2017/3035184

Protein-rich foods also lowers insulin in the blood stream so our blood sugar levels are more stable